Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$1.51
+2.0%
$1.65
$1.35
$5.92
$3.96M1.888,639 shs17,052 shs
Daxor Co. stock logo
DXR
Daxor
$9.80
+0.1%
$8.62
$7.11
$13.13
$46.45M-0.463,345 shs532 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.56
-0.2%
$3.82
$2.70
$11.68
$9.07M2.2643,882 shs27,569 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
+5.73%+5.00%-11.58%-24.03%-71.37%
Daxor Co. stock logo
DXR
Daxor
+0.10%+2.62%+17.93%+6.41%+979,999,900.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-0.22%+29.91%+9.88%+49.51%-59.86%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.3028 of 5 stars
3.53.00.00.01.10.00.6
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
3.00
Buy$10.00561.42% Upside
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A

Current Analyst Ratings

Latest NURO, AEMD, NVCN, and DXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/4/2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $10.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$570K6.95N/AN/A$6.56 per share0.23
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.54N/AN/A$13.18 per share0.35
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)
Daxor Co. stock logo
DXR
Daxor
N/AN/A0.00N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A

Latest NURO, AEMD, NVCN, and DXR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    
2/14/2024Q3 2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$1.23-$1.37-$0.14-$1.37N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/AN/AN/AN/AN/A
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/A
3.93
3.93
Daxor Co. stock logo
DXR
Daxor
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.99%
Daxor Co. stock logo
DXR
Daxor
1.34%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%

Insider Ownership

CompanyInsider Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
4.00%
Daxor Co. stock logo
DXR
Daxor
60.60%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
4.40%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
152.62 million2.52 millionNo Data
Daxor Co. stock logo
DXR
Daxor
N/A4.74 million1.87 millionNot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.90 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable

NURO, AEMD, NVCN, and DXR Headlines

SourceHeadline
Top Small-Cap Stocks for May 2023 - InvestopediaTop Small-Cap Stocks for May 2023 - Investopedia
news.google.com - May 13 at 9:38 AM
FDA accepts application for Roches Vabysmo for the - GlobeNewswireFDA accepts application for Roche's Vabysmo for the - GlobeNewswire
news.google.com - May 9 at 2:18 AM
New treatment option opens avenues in geographic atrophy - HealioNew treatment option opens avenues in geographic atrophy - Healio
news.google.com - May 8 at 9:18 PM
Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.comPachychoroid neovasculopathy has clinical properties that differ ... - Nature.com
news.google.com - May 8 at 9:18 PM
The NOD audit provides data and insights for the management for ... - Modern RetinaThe NOD audit provides data and insights for the management for ... - Modern Retina
news.google.com - May 8 at 9:18 PM
Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire
news.google.com - May 8 at 4:17 PM
Heart valve repair and replacement devices market size to grow by ... - BenzingaHeart valve repair and replacement devices market size to grow by ... - Benzinga
news.google.com - May 5 at 9:03 PM
ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times
news.google.com - May 5 at 4:02 PM
Faricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Press
news.google.com - May 5 at 12:24 AM
Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe
news.google.com - May 5 at 12:24 AM
STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine
news.google.com - May 4 at 7:24 PM
The NOD audit: Insights into the current state of management for ... - Nature.comThe NOD audit: Insights into the current state of management for ... - Nature.com
news.google.com - May 4 at 8:40 AM
On the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe
news.google.com - May 3 at 10:56 AM
Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars
news.google.com - April 28 at 3:22 PM
Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network
news.google.com - April 28 at 10:22 AM
Low-vision services improve vision, quality of life in patients with ... - HealioLow-vision services improve vision, quality of life in patients with ... - Healio
news.google.com - April 28 at 10:22 AM
New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire
news.google.com - April 25 at 6:55 PM
New treatment tackles both forms of AMD - Ophthalmology TimesNew treatment tackles both forms of AMD - Ophthalmology Times
news.google.com - April 25 at 6:55 PM
Price Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars
news.google.com - April 25 at 1:32 AM
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance
news.google.com - April 25 at 1:32 AM
Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotechAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotech
news.google.com - April 24 at 3:16 PM
Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular BusinessReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business
news.google.com - April 24 at 3:16 PM
Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics IndustryBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry
news.google.com - April 21 at 4:24 PM
The Future of the Structural Heart Disease Intervention Devices ... - Digital JournalThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journal
news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical logo

Aethlon Medical

NASDAQ:AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Daxor logo

Daxor

NASDAQ:DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.